NFKB1 and non-small cell lung carcinoma: Moreover, Morgillo et al. demonstrated that metformin increases the antitumor activity of MEK inhibitors in human LKB1-wild-type non-small cell lung cancer cell (NSCLC) lines by reducing the NF-kB (p65)-mediated transcription of MMP-2 and MMP-9 and through downregulation of GLI1 (142).